Evidence map›Paper›PMID 25038874›Full record

Trial reportGastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association2015

HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer.

Eric Van Cutsem, Yung-Jue Bang, Feng Feng-Yi, Jian M Xu, Keun-Wook Lee, Shun-Chang Jiao, Jorge León Chong, Roberto I López-Sanchez, Timothy Price, Oleg Gladkov and 7 more

2 registry-linked trialsOpen access · hybridAbstract readClinical Trial, Phase IIIRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 357 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
357citing papers in PubMed, 7 pooled it
19.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04168931 phase2terminatednot on this mapstarted 2020, after this paper: background citation

Efficacy of Adding Trastuzumab to Standard Chemotherapy in Patients With Advanced HER2-negative Gastric Cancer and HER2 Positive Expression in Circulating Tumor Cells

TypeinterventionalSponsorAC Camargo Cancer CenterRan2020 to 2023Enrolled5ConditionsGastric Cancer Stage IVArmsTrastuzumab
NCT05165602 unknown statusnot on this mapstarted 2022, after this paper: background citation

Evaluation of HER2-targeted Therapy for Gastric Cancer and Establishment and Verification of Monitoring System

TypeobservationalSponsorPeking UniversityRan2022 to 2023Enrolled30ConditionsHER2 Positive Gastric Cancer
3 · Its place in the literature

Who cites it

357 citing papers in PubMed, 7 syntheses or guidelines pooled it, 592 citations in OpenAlex.

  1. Pooled it
  2. HER2 discordance between primary and metastatic gastric cancer: a systematic review and meta-analysis.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Pooled it
  3. Pooled it
  4. Guideline
  5. Pooled it
  6. Clinical practice guidelines for esophagogastric junction cancer: Upper GI Oncology Summit 2023.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2024
    Guideline
  7. Pooled it
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Review
  19. Review
  20. Review

297 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 13 institutions in 10 countries.

Eric Van CutsemUniversity Hospitals Leuven and KU Leuven, Leuven, Belgium, eric.vancutsem@uzleuven.be.
Yung-Jue Bang
Feng Feng-Yi
Jian M Xu
Keun-Wook Lee
Shun-Chang Jiao
Jorge León Chong
Roberto I López-Sanchez
Timothy Price
Oleg Gladkov
Oliver Stoss
Julie Hill
Vivian Ng
Michaela Lehle
Marlene Thomas
Astrid Kiermaier
Josef Rüschoff
307th Hospital of Chinese People’s Liberation Army · CNChelyabinsk Regional Clinical Oncology Center · RUGenedata (Switzerland) · CHHospital Punta Pacifica · PAInstituto Nacional de Enfermedades Neoplásicas · PEKU Leuven · BEPeking University Cancer Hospital · CNQueen Elizabeth Hospital · AURoche (Bosnia-Herzegovina) · BARoche Pharma AG (Germany) · DERoche (Switzerland) · CHSeoul National University · KRSeoul National University Bundang Hospital · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn the Trastuzumab for GAstric cancer (ToGA) study, trastuzumab plus chemotherapy improved median overall survival by 2.7 months in patients with human epidermal growth factor receptor 2 (HER2)-positive [immunohistochemistry (IHC) 3+/fluorescence in situ hybridization-positive] gastric/gastroesophageal junction cancer compared with chemotherapy alone (hazard ratio 0.74). Post hoc exploratory analyses in patients expressing higher HER2 levels (IHC 2+/fluorescence in situ hybridization-positive or IHC 3+) demonstrated a 4.2-month improvement in median overall survival with trastuzumab (hazard ratio 0.65). The ToGA study provides the largest screening dataset available on HER2 overexpression/amplification in this indication. We further analyzed correlation(s) of HER2 overexpression/amplification with clinical and epidemiological factors.

methodsHER2-positivity was analyzed by histological subtype, tumor location, geographic region, and specimen type. Exploratory efficacy analyses were performed.

resultsThe HER2-positivity rate was 22.1 % across analyzed tumor samples. Rates were similar between European and Asian patients (23.6 % vs. 23.9 %), but higher in intestinal- vs. diffuse-type (31.8 % vs. 6.1 %), and gastroesophageal junction cancer versus gastric tumors (32.2 % vs. 21.4 %). Across all IHC scores, variability in HER2 staining (≤30 % stained cells) was observed in almost 50 % of cases, with increasing rates in lower IHC categories, and did not affect treatment outcome. The polysomy rate was 4 %.

conclusionsHER2 expression varies by tumor location and type. All patients with advanced gastric or gastroesophageal junction cancer should be tested for HER2 status, preferably using IHC initially. Due to the unique characteristics of gastric cancer, specific testing/scoring guidelines should be adhered to.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsErb-b2 Receptor Tyrosine KinasesEsophageal NeoplasmsEsophagogastric JunctionHumansImmunohistochemistryIn Situ Hybridization, FluorescenceMolecular Targeted TherapyStomach NeoplasmsTrastuzumabTreatment OutcomeERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesTrastuzumab

Identifiers

PMID25038874
PMCPMC4511072
OpenAlexW2136197678

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.